Core Insights - MetaVia Inc. is set to present its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026 [1] - The company is developing DA-1726, an oxyntomodulin analogue, for obesity treatment, and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is publicly traded on Nasdaq under the ticker MTVA [1] Product Pipeline - DA-1726 is a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [1] - In a Phase 1 trial, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction [1] - Vanoglipel is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation and glucose metabolism in pre-clinical studies [1] - In a Phase 2a clinical study, vanoglipel exhibited direct hepatic action alongside glucose-lowering effects [1]

Core Insights - MetaVia Inc. has announced a strong global intellectual property portfolio for its lead asset, DA-1726, which is aimed at treating obesity and related metabolic disorders, securing 39 granted and pending patents that extend protection until 2041 [1][2] Company Performance - The company's CEO highlighted the significance of the intellectual property, emphasizing the unique design of DA-1726 as a dual GLP-1/glucagon agonist, with recent clinical data showing a 9% weight loss at the 48 mg dose and improvements in waist size and blood sugar levels [2] - MetaVia's stock is currently trading 21.8% below its 20-day simple moving average and 77.6% below its 200-day SMA, indicating significant bearish pressure, with shares down 90.85% over the past 12 months [3] - The stock's RSI is at 23.34, suggesting it may be undervalued and could rebound, while the MACD indicates potential bullish momentum despite the overall bearish trend [4] Sector Comparison - MetaVia is outperforming its sector with a gain of approximately 10.2%, while the Healthcare sector has only increased by 0.17%, reflecting a significant deviation from recent sector trends [5] - The Healthcare sector has seen a slight decline of 1.18% over the past 30 days but has gained 2.83% over the last 90 days, indicating mid-tier performance in the market [5] Analyst Consensus - The stock carries a Buy Rating, with recent analyst actions including HC Wainwright & Co. raising the target price to $40.00 [6] - At the time of publication, MetaVia shares were up 9.64% at $1.84, trading near its 52-week low of $1.61, with key resistance at $2.00 and support at $1.50 [6]

ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candi ...

Core Viewpoint - MetaVia Inc. has successfully closed an underwritten public offering, raising approximately $9.3 million for the development of its cardiometabolic disease treatments [1][3]. Group 1: Offering Details - The public offering included 3,005,574 shares of common stock and 9,016,722 warrants (4,508,361 Series C Warrants and 4,508,361 Series D Warrants) at a price of $3.10 per share [2]. - The Series C and Series D Warrants are immediately exercisable at an exercise price of $3.10, with Series C expiring in five years and Series D in two years [2]. - The Series D Warrants can be called by the company following a positive data readout from its Phase 1b Part III clinical trial for DA-1726 [2]. Group 2: Financial Implications - If fully exercised, the warrants could yield up to approximately $28.0 million in future gross proceeds [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes, specifically to continue the clinical development of DA-1726 for obesity treatment [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [7]. - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, showing potential for superior weight loss and glucose control [7]. - Vanoglipel (DA-1241) is a GPR119 agonist that has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [7].

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite increasing by approximately 1% on Thursday. The Dow rose by 0.80% to 49,543.16, while the S&P 500 gained 0.74% to 6,977.92 [1] - Information technology shares experienced a gain of 1.5%, while health care stocks saw a decline of 1.5% on the same day [1] Economic Indicators - U.S. initial jobless claims decreased by 9,000 to 198,000 for the week ending January 10, which was better than market expectations of 215,000 [2][10] - The NY Empire State Manufacturing Index increased to 7.7 in January, significantly up from a revised reading of -3.7 in December, surpassing market estimates of 1 [10] - The Philadelphia Fed Manufacturing Index rose by 21.4 points to a reading of 12.6 in January [10] Commodity Prices - Oil prices fell by 4.7% to $59.08, while gold decreased by 0.4% to $4,618.80. Silver and copper also saw declines of 1.1% to $90.405 and 1.5% to $5.9660, respectively [5] Company News - Callan JMB Inc. shares surged by 208% to $3.45 following a strategic teaming agreement with Biostax Corp [9] - Springview Holdings Ltd experienced a 290% increase in shares to $8.96 after announcing a partnership with Jiangsu GSO New Energy Technology Co., Ltd [9] - authID Inc. shares rose by 99% to $1.98 due to an integration announcement with ServiceNow [9] - MetaVia Inc. shares dropped by 40% to $3.26 after pricing an $8.1 million underwritten public offering [9] - Caledonia Mining Corporation PLC shares fell by 19% to $26.39 after announcing a $125 million offering of convertible senior notes [9] - TryHard Holdings Limited shares decreased by 41% to $19.00 following a Memorandum of Cooperation with STAR PARTY HK LIMITED [9]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite increasing by approximately 1% on Thursday. The Dow rose by 0.80% to 49,543.16, while the S&P 500 gained 0.74% to 6,977.92 [1] - Information technology shares experienced a gain of 1.5%, while health care stocks saw a decline of 1.5% on the same day [1] Job Market - Initial jobless claims in the U.S. decreased by 9,000 to 198,000 for the week ending January 10, which was better than market expectations of 215,000 [2][10] Commodity Prices - Oil prices fell by 4.7% to $59.08, while gold decreased by 0.4% to $4,618.80. Silver and copper also saw declines of 1.1% to $90.405 and 1.5% to $5.9660, respectively [5] European Market Overview - European shares displayed mixed results, with the eurozone's STOXX 600 rising by 0.39%, while Spain's IBEX 35 Index fell by 0.21%. London's FTSE 100 gained 0.56%, Germany's DAX rose slightly by 0.01%, and France's CAC 40 slipped by 0.23% [6] Asian Market Overview - Asian markets closed lower, with Japan's Nikkei down by 0.42%, Hong Kong's Hang Seng Index declining by 0.28%, and China's Shanghai Composite falling by 0.33% [7] Company News - Callan JMB Inc. shares surged by 208% to $3.45 following a strategic teaming agreement with Biostax Corp [9] - Springview Holdings Ltd saw a significant increase of 290% to $8.96 after announcing a partnership with Jiangsu GSO New Energy Technology Co. for solar solutions in Singapore [9] - authID Inc. shares rose by 99% to $1.98 due to an integration announcement with ServiceNow [9] - MetaVia Inc. shares dropped by 40% to $3.26 after pricing an $8.1 million public offering [9] - Caledonia Mining Corporation PLC shares fell by 19% to $26.39 after announcing a $125 million offering of convertible senior notes [9] - TryHard Holdings Limited shares decreased by 41% to $19.00 following a memorandum of cooperation with STAR PARTY HK LIMITED for a potential joint venture in Japan [9]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points, up 0.41% to 49,352.44, while the NASDAQ rose 0.78% to 23,655.17, and the S&P 500 gained 0.55% to 6,964.89 [1] Sector Performance - Information technology shares saw a gain of 1.4%, while health care stocks experienced a decline of 1% on the same day [2] Company Earnings - The Goldman Sachs Group, Inc. reported strong fourth-quarter earnings, posting $14.01 per share, surpassing the analyst consensus estimate of $11.65 per share. However, quarterly sales of $13.454 billion fell short of the analyst consensus estimate of $13.791 billion [3] Commodities - In commodity markets, oil prices decreased by 4.6% to $59.15, gold fell by 0.5% to $4,611.40, silver dropped 2.3% to $89.285, and copper declined by 2% to $5.9385 [6] European Market Performance - European shares showed mixed results, with the eurozone's STOXX 600 rising by 0.4%, while Spain's IBEX 35 Index fell by 0.3%. London's FTSE 100 and Germany's DAX both gained 0.4% and 0.2% respectively, while France's CAC 40 slipped by 0.1% [7] Asian Market Performance - Asian markets closed lower, with Japan's Nikkei down 0.42%, Hong Kong's Hang Seng Index declining by 0.28%, and China's Shanghai Composite falling by 0.33% [8] Notable Stock Movements - Callan JMB Inc. shares surged by 244% to $3.8499 following a strategic agreement with Biostax Corp. Springview Holdings Ltd. shares increased by 176% to $6.35 after announcing a partnership for solar solutions in Singapore. authID Inc. shares rose by 91% to $1.89 due to an integration announcement with ServiceNow. Conversely, MetaVia Inc. shares dropped by 44% to $3.15 after pricing a public offering, and Inspire Veterinary Partners, Inc. shares fell by 38% to $0.0510 after a significant stock increase the previous day. TryHard Holdings Limited shares decreased by 35% to $20.54 following a joint venture announcement [9]

Core Viewpoint - MetaVia Inc. has announced the pricing of its underwritten public offering, aiming to raise approximately $8.1 million before expenses and potential future proceeds from warrant exercises [1] Company Summary - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The offering includes shares of common stock, Series C Warrants, and Series D Warrants [1] Financial Summary - The gross proceeds from the public offering are approximately $8.1 million, excluding underwriting discounts, commissions, and offering expenses [1]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 12, 2026 Registration No. 333-292581 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hyung Heon Kim President, Chief Executive Officer and Director 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 (857) 702-9600 (Name, address, including zip code, and telephone number, including area code, of agent for servic ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphic METAVIA INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (IRS Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 2834 47-2389984 545 C ...